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In this study, phosphonate-terminated magnetic mesoporous nanoparticles (pMMSNs) was
designed by incorporation of MNPs in the center of mesoporous silica nanoparticles (MSNs)
and followed by grafting phosphonate group on to the surface of MMSNs. The carrier
exhibited a typical superparamagnetic feature and the saturation magnetization was
4.89 emu/g measured by vibrating sample magnetometer (VSM). pMMSNs had a spherical
morphology and a pore size of 2.2 nm. FromN2 adsorption-desorption analysis, pMMSNshad
a surface area of 613.4 m2/g and a pore volume of 0.78 cm3/g. Phosphonate modification
improved the colloidal stability of MMSNs, and the hydrodynamic diameter of pMMSNs was
around 175 nm. The hydrophilic phosphonate group significantly enhanced the negative
surface charge of MMSNs from 19.3 mV to 28.8 mV pMMSNs with more negative surface
charge had a 2.3-fold higher drug loading capacity than that of MMSNs. In addition, the rate
and amount of release of doxorubicin (DOX) from DOX/pMMSNs was pH-dependent and
increased with the decrease of pH. At pH 7.4, the release amount was quite low and only
approximately17wt%ofDOXwasreleased in48h.AtpH5.0and3.0, therelease rate increased
significantly and the release amount achieved 31 wt% and 60 wt% in 48 h, respectively. To
evaluate themagnetic targetingperformanceof pMMSNs, FITC labeledpMMSNswas injected
intomice bearing S180 solid tumor. FITC labeledpMMSNs controlled by an externalmagnetic
field showed higher tumor accumulation and lower normal tissue distribution.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.; fax: þ86 24 23986348.
, silingwang@hotmail.com (S. Wang).
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Magnetic targeting drug delivery systems (MTDDS) based on
magnetic nanoparticles and externalmagnetic field have been
considered as a promising approach for localized accumula-
tion of chemotherapeutical agent at the tumor sites [1,2].
Compared with traditional nanotechnology, MTDDS possess
the advantages of ease preparation, facile response to external
magnetic field and low cost. Moreover, many drug delivery
systems depended on the blood circulation can hardly be
transported to the tumor sites due to the formation of neo-
vessels, which are often distorted and irregular [3]. Develop-
ment of MTDDS requires high magnetic susceptibility for
optimum magnetic enrichment and loss of magnetization
after removal of magnetic field [4]. Concerning the vascular
administration of MNPs, good colloidal stability is required.
Great efforts have been made to encapsulate MNPs with
various shells, such as, polymeric stabilizers and surfactants,
e.g., dextran, poly (vinyl alcohol) (PVA), poly (ethylene glycol)
(PEG) or oxide surfaces (e.g., SiO2) to ensure biocompatibility,
water dispersibility, as well as appropriated functionalization
for further conjugation with bioactive molecules or targeting
ligands [5]. In the past decade, mesoporous silica coatedMNPs
have received much attention due to their advantages: (1)
MSNs protect MNPs from being eroded by acidic body fluid; (2)
very high surface area and pore volume for drug loading; (3)
versatile silanol groups render further modification; (4) good
biocompatibility [6,7].
Considering the acidic environment at the tumor sites and
more acidic pH of internal cell organelles (pH 4.0e5.0 in the ly-
sosomes and pH6.0 near the cancer cellmembrane) it waswise
to designMTDDSpossessingpH-stimuli release feature [8,9]. Qu
et al. prepared Eudragit-S100 coated MMSNs, which showed
high release rate and amount of ibuprofen in simulated prox-
imal intestine fluid, but the polymerwas insoluble in simulated
gastric fluid resulting in low release accumulation [10]. Yang
et al. designedMMSNs coatedwith a pH sensitive polymer poly
methacrylic acid (PMAA). The release rate of doxorubicin from
thecarrierwasfasterbelowitspKa thanthatofabove itspKa [11].
The purposes of this study were to incorporate MNPs into
the center of MSNs and modify the surface with the hydro-
philic phosphonate group (pMMSNs). The phosphonate-
termination improved the drug loading capacity of MMSNs
by increasing the negative surface charge of MMSNs resulting
in a stronger electrostatic interaction between the positively
charged DOX andmore negatively charged pMMSNs. The DOX
release profiles at pH 3.0, 5.0 and 7.4 were significantly
different due to the electronic repulsion between DOX and the
carriers. FITC labeled pMMSNs were prepared to evaluate the
magnetic targeting efficiency of this carrier in vivo under the
control of an external magnetic field.2. Materials and methods
2.1. Materials
Doxorubicin (DOX) in the form of hydrochloride salt was
obtained from Haizheng Drug Company (Zhejiang, China).FeCl3$6H2O, FeSO4$7H2O, oleic acid, and Tetraethyl orthosili-
cate (TEOS) were purchased from Bodi Reagent Company
(Tianjin, China). Fluorescein isothiocyanate (FITC) and 3-
aminopropyl triethoxysilane (APTES) were purchased from
Aladdin (Shanghai, China). Trihydroxyl Silyl Proply Methyl
Phosphonate (THPMP) was obtained from SigmaeAldrich (St.
Louis, MO, USA). Other chemicals were of reagent grade and
were used without further purification.
2.2. Animals
The male Kunming mice weighing 20e22 g were purchased
from the Experimental Animal Center of Shenyang Pharma-
ceutical University (Shenyang, China). The animal care and
experiments were performed in accordance with the guide-
lines of the local Animal Welfare Committee.
2.3. Preparation of pMMSNs
2.3.1. Preparation of MNPs
Oleic acid stabilized magnetic nanoparticles (MNPs) were
prepared via a modified coprecipitation method reported
previously [12]. The oleic acid stabilized magnetic nano-
crystals were placed in chloroform and the concentration of
the magnetic solid was adjusted to 7.5 mg/ml.
2.3.2. Preparation of MMSNs and pMMSNs
pMMSNs were produced by modified solegel method [13].
MNPs dispersed in chloroform (1 ml) were added to an
aqueous solution of cetyltrimethyl ammonium bromide
(CTAB) (20 ml, 12.5 mg/ml) under vigorous ultrasonic to pro-
duce a homogeneous oil-in-water microemulsion. Then,
chloroform was evaporated by heating at 85 C to form CTAB
stabilized MNPs. And then the system was diluted by distilled
water and the pH was adjusted to 12. When temperature was
stabilized in 80 C, 1ml ethanol wasmixedwith 1ml TEOS and
then the mixture was added slowly to the aqueous solution
containing the CTAB stabilized MNPs. 30 min later, THPMP
was added. The solution was stirred for another 3 h followed
by collecting the colloidal nanoparticles through centrifuga-
tion. CTAB was removed by dispersing the washed sample in
100 ml ethanol solution containing 12 mg/ml ammonium ni-
trate and heating themixture at 70 C for 6 h. The product was
then washed with water and ethanol to obtained
phosphonate-terminated MMSNs (pMMSNs). MMSNs without
phosphonate modification were also prepared but in the
absence of THPMP.
2.3.3. Preparation of FITC labeled pMMSNs
1mg of fluorescein isothiocyanate (FITC) was dissolved in 1ml
absolute ethanol and mixed with 20 ml of 3-aminopropyl
triethoxysilane (APTES) for 10 h. 100 mg of pMMSNs was re-
dispersed in 100 ml absolute ethanol and heated to 80 C.
After the temperature was stabilized, 0.5 ml of the ethanolic
FITC-APTES solution was added slowly to the ethanolic solu-
tion containing pMMSNs. The mixture was stirred for 6 h. The
synthesized product was re-dispersed in 100 ml of ethanol
solution containing 12 mg/ml ammonium nitrate and heating
the mixture at 70 C for 6 h. The product was then washed
with water and ethanol to obtain FITC-pMMSNs.
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Positively charged DOXwas selected as a model drug. In order
to enhance the drug loading capacity, two-steps drug loading
process was adopted involving adsorption equilibrium and
solvent evaporation. Typically, the adsorption of DOX into
mesopores of pMMSNs was carried out by adding pMMSNs to
4 ml of DOX solution (2 mg/ml). The drug/carrier ratio in the
loading solution was fasten to 1: 10 (w/w) and then the hybrid
was mixed under ultrasonic for 1 h and stirred at room tem-
perature to achieve maximum loading for another 24 h. The
process was in a closed container to prevent ethanol evapo-
ration. Finally, the container was opened and ethanol as the
solvent was evaporated at 37 C. The DOX loaded carrier was
continually dried at 40 C under vacuum to remove solvent
residue. The drug loaded samples were labeled with DOX/
pMMSNs.
2.5. Characterization techniques
The morphology of the samples plated with gold was char-
acterized using TEM (Tecnai G2 20, FEI, USA). Nitrogen
adsorption isotherms at 196 C were measured using a ni-
trogen adsorption analyzer (V-Sorb 2800P, China). The carriers
were degassed to remove physically adsorbed water before
analysis. The magnetic curves were analyzed by vibrating
magnetometer (Lake Shore 7410, USA) at 300 K. The hysteresis
of the magnetization was obtained by changing H between
þ10,000 Oe and 10,000 Oe. The hydrodynamic diameter, PDI
and zeta potential of the samples were measured by photo
correlation spectroscopy using a Zetasizer nano (Nano ZS,
Malvern Co., UK). TGA-50 instrument (Shimadzu, Japan) was
also employed to calculate the weight percentage of phos-
phonate groups grafted on to the surface MMSNs.
2.6. Analysis of drug content
To determine the drug loading capacity, DOX/MMSNs and
DOX/pMMSNs were resuspended in methanol and sonicated
for 2 h. The concentration of DOX of the supernatant was
determined by ultraviolet (UV) spectroscopy (UV-2000, Unico,
USA), while the detection wavelength was 480 nm. The stan-
dard curves were linear over the concentration range of
1.0e30 mg/ml. The drug loading capacity (DLC) was calculated
by the following equation: DLC ¼ WDOx/WDOx-carrier. Where
WDOx is the weight of DOX loaded and WDOx-carrier is the
weight of DOX loaded carrier.
2.7. In vitro DOX release study
A typical in vitro drug release experiment was performed as
follows. An aliquot of 20 mg of drug/carrier composite was
immersed in 20 ml of 0.1 M phosphate buffer solution of
required pH (pH 3.0, pH 5.0 and pH 7.4). The release medium
was stirred at 100 rpm and at 37 C. At predetermined sam-
pling time, 4 ml of medium was extracted for measurement,
and then put back to the container. The amount of DOX in the
medium was determined by UV-spectroscopy at a detection
wavelength of 480 nm for all pH values. The experiments were
performed in triplicate.2.8. Ex vivo tissue imaging
The in vivo imaging system (FX Pro, Kodak, USA) was applied
to evaluate the magnetic targeting efficiency of pMMSNs
controlled by an external magnet field in Kunming mice
bearing S180 tumor. Briefly, when tumor sizes reached
1500 mm3, mice were received the FITC labeled pMMSNs
(10 mg/ml) intravenously and the blank group receive saline.
The test group was then treated with permanent magnet
attached to the surface of the tumor of the mice for 1 h. Mice
were scarified at 2 h, and then tumor and normal tissues were
imaged with appropriate wavelength (lex: 480 nm, lem:
535 nm).3. Results and discussion
3.1. Preparation of MNPs, MMSNs and pMMSNs
In this study, MNPs were synthesized according to the tradi-
tional coprecipitation method and stabilized with oleic acid
[13]. A simple solegel method was applied to prepare mono-
dispersed MNPs embedded in mesoporous silica shell.
Scheme 1 shows a typical synthetic process of pMMSNs in. As
previously reported, pre-existing CTAB stabilized MNPs
served as the nucleation seeds [13,14]. Under basic conditions,
the silica oligomerswhichwere generated by the hydrolysis of
TEOS, self-assembled with surfactant micelles to form CTAB/
silica mesostructured nano-composites, which subsequently
deposited on the magnetic seeds to construct the shell
framework. However, in the case of MSNs, the mesostruc-
tured nano-composites aggregated together directly and grew
to the whole particle by further condensation of silica species.
CTAB served not only as the organic template for the forma-
tion of mesopores but also as the secondary surfactant to
transferMNPs fromorganic solvent to aqueous phase [15]. The
surface of MMSNs was modified with hydrophilic phospho-
nate groups shortly after the particle formation resulted in
increased stability and dispersibility of the carrier in aqueous
solution even after drying process. Previous research had re-
ported that MMSNs easily aggregated and settled to the bot-
tom quickly after drying and re-dispersing process. The
irreversible aggregation might be attributed to the interpar-
ticle hydrogen-bonding interaction between the surface sila-
nol groups and can be prevented by grafting hydrophilic
molecules on to the surfaces [16,17].
3.2. Characterization of MNPs, MMSNs and pMMSNs
Fig. 1A presents the TEM images of oleic acid modified MNPs
with a diameter of around 10 nm. However, the nanoparticles
showed a slight aggregation. MNPs with a diameter of about
10 nm behaved superparamagnetism which meant that they
weremagnetic only under the controlled of external magnetic
field and became inactive once the external magnetic field is
removed. Fig. 1B shows that pMMSNs were discrete spheres
with a diameter of around 100 nm. The appearance of the
pores was distorted and ran radically to the surface. MNPs
were individually imbedded in the center of silica shell due to
vigorous ultrasonic stirring in the stage of transforming MNPs
Scheme 1 e Schematic preparation process of MMSNs, pMMSNs, DOX loaded pMMSNs.
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supplied to further DOX laden.
The pore structure of MMSNs and pMMSNsweremeasured
through N2 adsorption-desorption analysis. Fig. 2A shows the
N2 adsorption isotherms of MMSNs and pMMSNs, which were
typical type IV isotherms with two steps confirming their
mesoporous structure according to the IUPAC classification.
Compared with MMSNs, the adsorbed nitrogen amount of
pMMSNs was slightly reduced, but the shape of the hysteresis
remained unchanged. The BET surface area, pore volume and
pore diameter of MMSNs were 923.6 m2/g, 1.48 cm3/g and
2.8 nm, respectively. The parameters of pMMSNs were
reduced to 613.4 m2/g, 0.78 cm3/g, and 2.2 nm, respectively
(Table 1). These results suggested that phosphonate-
termination did not destruct the pore structure. However,
phosphonate-group distributed on the interior pore walls and
exterior surface of MMSNs occupied some pore space which
could be used to storage drugs molecules.
Fig. 3 illustrates the field-dependent magnetization curves
of MNPs, MMSNs and pMMSNs measured at 300 K. They
exhibited a typical superparamagnetism and no hysteresis
was observed in low fields. The saturatedmagnetization value
of MNPs was 37.5 emu/g. But it dramatically decreased to
6.74 emu/g and 4.89 emu/g for MMSNs and pMMSNs. AsFig. 1 e TEM images of (A) Mshown in Fig. 3 (inserted), pMMSNs with superparamagnetic
characteristic and high magnetization value could quickly
respond to external magnetic field and redisperse in aqueous
solution once the external magnetic field was removed and
with gentle shaking or sonication.
Fig. 4 shows the thermogravimetric analysis (TGA) of
MMSNs and pMMSNs. The decline in the curves started from a
low temperature of about 50 C. Thismight be attributed to the
evaporation of absorbed water tightly bound to the carriers.
TGA curves demonstrated that the weight loss of MMSNs was
6 wt%, while that of pMMSNs was 14.9 wt%. Thus, the content
of phosphonate-termination was about 8.9 wt %.
The particle sizes and zeta potential measurements of
MMSNs and pMMSNs were performed using dynamic light
scatter (DLS) technique to evaluate the dispersibility, stability
and surface charge potential after each preparation steps
(Table 2). BareMMSNs had a negative surface charge of around
20 mV in PBS solution at pH 7.4, mean hydrodynamic
diameter of 166.4 nm and a narrow PDI of 0.201. The particle
size measured by DLS was higher than the particle size
observed from TEM image of that sample. This could be
attributed to the formation of hydrodynamic shell of MMSNs
and slight aggregates between nanoparticles. The hydrody-
namic diameter and PDI of pMMSNs were 175 nm and 0.218,NPs and (B) pMMSNs.
Fig. 2 e (A) N2 adsorption-desorption isotherms and (B) pore size distributions of MMSNs and pMMSNs.
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aqueous solution, MMSNs without phosphonate modification
easily aggregated and settled down to the bottom. On the
other hand, pMMSNs were stable when re-dispersed in
aqueous solution, and their hydrodynamic size and PDI
showed a slight increasement. Moreover, pMMSNs leaded to
more negative surface charge value of 28.8 mV in PBS solu-
tion at pH 7.4. This could be explained that the phosphonate
groups have a higher pKa value than that of the silanol groups.
3.3. Drug loading capacity (DLC) and in vitro release
study
In this study, positively charged DOX was selected as a model
drug to investigate the drug loading capacity (DLC) of the
carriers and to study the pH-dependent release of DOX/
pMMSNs. Table 1 shows that the DLC of pMMSNs (6.9 wt%)
was higher than that of MMSNs (2.8 wt%). The probable rea-
sons for the enhanced DLC of DOX in pMMSNs were as fol-
lows. The electronic attraction between negatively charged
carriers and positively surface charge of DOX might be the
main factor that affected DLC. Even though, pMMSNs had
lower surface area and pore volume than that of MMSNs, the
DLC value of DOX/pMMSNs was 2.3-fold higher than that of
DOX/MMSNs. Therefore, we could speculate that the surface
area and pore volume of pMMSNs were high enough for DOX
incorporation.
Drug delivery systems with the pH-responsive release
profile mean that drugs do not or hardly release in normal
tissues and blood (pH ~ 7.4), but can responsively release inTable 1 e Characteristics of MMSNs and pMMSNs.
Sample SBET
a
(m2/g)
Vt
b
(cm3/g)
DBJH
c
(nm)
Drug loading
capacity
(wt%)
Saturation
magnetization
(emu/g)
MMSNs 923.6 1.48 2.8 2.8 6.74
pMMSNs 613.4 0.78 2.2 6.9 4.89
SBET
a is the BET surface area calculated using experimental points at
a relative pressure of P/P0. Vt
b is the total pore volume determined at
a relative pressure of 0.9814. DBJH
C is the pore diameter calculated by
the BJH method on the branches of the nitrogen desorption
isotherms.tumor tissues, or even within cancer cells, to selectively kill
cancer cells (pH 3.0e5.0) [18]. The release profiles of DOX from
DOX/MMSNs and DOX/pMMSNs were investigated in PBS so-
lution at three different pH. The pH 3.0 and pH 5.0 represented
the acidic environment of tumor tissues, while pH 7.4 repre-
sented the neutral pH of normal tissues and blood. On the
whole, the observed release rate and amount of DOX from
DOX/MMNSs and DOX/pMMSNs increased with the decrease
in the pH values. Fig. 5A shows that, at pH 3.0, the release rate
of DOX from DOX/MMSNswas relatively fast and 63% amount
of DOX diffused to release medium at 48 h. At pH 5.0, the
release rate and amount of DOX from DOX/MMSNs were
decreased reached 51% at 48 h. However, at pH 7.4, the release
curve of DOX fromDOX fromDOX/MMSNswas almost flat and
the release accumulation was 14%. The reasons for this phe-
nomenon was that amine groups from doxorubicin are
partially deprotonated at pH 7.4 (pKa ¼ 8.22), while they are
fully protonated at pH 3.0 and 5.0. On the other hand, MMSNs
have a higher total positive charge at pH 5.0 and even higher
positive charge at pH 3.0 because of the presence of surface
silanol groups (pKa ¼ 6.8) [19]. Therefore, the electronic
repulsion between DOX and the carrier contributed to the
pH-dependent release profile of DOX/MMSNs.Fig. 3 e Field-dependent magnetization of MNPs, MMSNs
and pMMSNs and photograph demonstrating high
magnetic responsiveness of pMMSNs with an external
magnetic field (inserted).
Table 2 e Hydrodynamic size, size distribution and zeta
potential values of MMSNs and pMMSNs.
Sample Hydrodynamic
size (nm)
PDI Zeta potential
(mV)
MMSNs 166.4 ± 14.3 0.201 ± 0.012 19.3
pMMSNs 175.7 ± 11.4 0.218 ± 0.0089 28.8
pMMSNs
(drying and
re-dispersing)
232.5 ± 10.9 0.267 ± 0.023 e
Fig. 4 e TGA curves of MMSNs and pMMSNs at 300 K.
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phosphonate modified MMSNs (pMMSNs) in PBS solution at
three different pH. At pH 3.0, the release pattern showed a
burst release amount of 31% at the initial 4 h and then the
release rate turned slow to reach a total release accumulation
of 60%. At pH 5.0, the release rate and amount of DOX from
DOX/pMMSNs decreased and only 43% of DOX dissolved in the
medium. At pH 7.4, the whole release amount of DOX from
DOX/pMMSNs was also incomplete with a final accumulation
of 17% at 48 h. The reasons for the sustained release behavior
of DOX from phosphonate modified carrier may be that
phosphonate modification made the surface charge potential
of MMSNs even more negative, thus the attractive interactionFig. 5 e In vitro release profiles of DOX from (A) DOX/MMSNs abetween DOX and pMMSNs was stronger than the attractive
force between DOX and MMSNs.
3.4. In vivo distribution of pMMSNs (MFþ) and
pMMSNs (MF)
To demonstrate that pMMSNs could be controlled by external
applied magnetic field, FITC labeled pMMSNs was injected
intravenously into mice bearing S180 tumor. The test group
then was fixed with an external magnetic field at the solid
tumor for 1 h, referred to as pMMSNs (MFþ). The contrast group
also received the same formulation but without an applied
magnetic field (MF). Also, mice received saline was treated as
controlled group. Since the FITC fluorescence signal had poor
penetration ability in deep tissues and the background fluo-
rescence intensity ofmicewashigh,micewere sacrificed at 2 h
after administration and ex vivo fluorescence intensity images
of the major organs and tumors were obtained, as shown in
Fig. 6. The fluorescence intensities in the heart and spleen of
mice of the two groups were very low. Enhanced fluorescence
intensity was observed in the tumor of mice treated with
pMMSNs (MFþ). On the other hand, the fluorescence intensity
in liver and lung of mice treated with pMMSNs (MF) was
obviouslyhigher than that ofmice treatedwithpMMSNs (MFþ).
This phenomenon was attributed to that without external
magnetic field, the discontinuous gaps in the endothelium
which lines the sinusoidal walls of liver allow the passive
entrapment of pMMSNs [20,21]. Moreover, macrophages in
liver had great association with the nanoparticles than other
types of cells [22]. The high lung affinity of pMMSNswas due to
hydrodynamic size increased in serum which leaded to tran-
sient association with capillary in lung. A high tumor accu-
mulation of pMMSNs (MFþ) demonstrated the feasibility of
our designed magnetic targeting drug delivery system.4. Conclusion
The resultsof thispapershowedthatphosphonate-terminated
magnetic mesoporous silica nanoparticles (pMMSNs) with a
saturation magnetization of 4.89 emu/g and a hydrodynamic
diameter of around 175 nm were prepared. The negative
surface charge (28.8 mV) and surface area of 613.4 m2/g
warranted successful loading of DOX using a two-stepsnd (B) DOX/pMMSNs in PBS solution at pH 3.0, 5.0 and 7.4.
Fig. 6 e Ex vivo optical images of tumors and other organs of S180 tumor bearing mice sacrificed at 2 h after intravenous
injection of FITC labeled pMMSNs. (A) S180 tumor bearingmice treated with saline; (B) S180 tumor bearingmice treated with
pMMSNs (MF¡); (C) S180 tumor bearing mice treated with pMMSNs (MFþ).
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ration. The in vitro release profiles of DOX/pMMSNs were pH-
depended. At lower pH (3.0 and 5.0), DOX release rate and
release amount of DOX was higher compared to that of at pH
7.4 and this can be attributed to the decreased electrostatic
interaction between the negative surface charge of pMMSNs
and the entrapped DOX from the nanoparticles. Moreover,
ex vivo tissue fluorescence intensity measurement showed
that under the facilitation of external magnetic field, the dis-
tribution of pMMSNs (MFþ) was improved via a higher tumor
retention and lower distribution in normal tissues than that of
pMMSNs (MF). We believe that these results may open the
possibilities for combining magnetic targeting drug delivery
systemandpH-responsive release of doxorubicin to cancerous
tissue.r e f e r e n c e s
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